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Available online 14 May 2016Oxytocin is involved in the control of different behaviors, from sexual behavior and food consumption to empa-
thy, social and affective behaviors. An imbalance of central oxytocinergic neurotransmission has been also asso-
ciatedwith differentmental pathologies, fromdepression, anxiety and anorexia/bulimia to schizophrenia, autism
and drug dependence. This study shows that oxytocin may also play a role in the control of locomotor activity.
Accordingly, intraperitoneal oxytocin (0.5–2000 μg/kg) reduced locomotor activity of adult male rats. This effect
was abolished by d(CH2)5Tyr(Me)
2-Orn8-vasotocin, an oxytocin receptor antagonist, given into the lateral ven-
tricles at thedose of 2 μg/rat,whichwas ineffective on locomotor activity. Oxytocin (50–200 ng/site) also reduced
and d(CH2)5Tyr(Me)2-Orn8-vasotocin (2 μg/site) increased locomotor activity when injected bilaterally into the
substantia nigra, a key area in the control of locomotor activity. Conversely, the destruction of nigral neurons
bearing oxytocin receptors by the recently characterized neurotoxin oxytocin-saporin injected into the
substantia nigra, increased basal locomotor activity. Since oxytocin-saporin injected into the substantia nigra
caused amarked reduction of neurons immunoreactive for tyrosine hydroxylase (e.g., nigrostriatal dopaminergic
neurons) and for vesicular glutamate transporters VGluT1, VGluT2 and VGluT3 (e.g., glutamatergic neurons), but
not for glutamic acid decarboxylase (e.g., GABAergic neurons), together these ﬁndings suggest that oxytocin in-
ﬂuences locomotor activity by acting on receptors localized presynaptically in nigral glutamatergic nerve termi-
nals (which control the activity of nigral GABAergic efferent neurons projecting to brain stem nuclei controlling
locomotor activity), rather than on receptors localized in the cell bodies/dendrites of nigrostriatal dopaminergic
neurons.








Oxytocin, the neurohypophyseal hormone well known for its
hormonal role in lactation and parturition, also exerts widespread actions
in central nervous system. Accordingly, a physiological role of this neuro-
peptide is thought to occur in the control of different behaviors, from
sexual behavior and food consumption to empathy, social and affective
behaviors (Argiolas and Melis, 2013, Crespi, 2015; Feeser et al., 2012;
Liu and Wang, 2003; Lin, 2012; Parker and Bloom, 2012; Gil et al., 2013;
Štefánik et al., 2015). An imbalance of central oxytocinergic neurotrans-
mission is also thought to be associatedwith differentmental pathologies,
from depression, anxiety and anorexia/bulimia to schizophrenia, autism
and drug dependence (Baskerville and Douglas, 2010; Love, 2014;
Sarnyai and Kovács, 2014; Guastella et al., 2015). The involvement of oxy-
tocin in the above central functions and mental pathologies is supportedrtment of Biomedical Sciences,
della Universitaria, SS 554, Km
c. This is an open access article underby the existence of hypothalamic oxytocinergic neurons that project not
only to the neurohypophysis but also to multiple extra-hypothalamic
brain areas, such as the nucleus accumbens, the medial frontal cortex,
the ventral tegmental area, the substantia nigra, the hippocampus, the
amygdala, the medulla oblongata and the spinal cord (Buijs, 1978;
Dogterom et al., 1978; Mai et al., 1993; Sofroniew, 1980; Zimmerman
et al., 1984). For instance, at the level of the ventral tegmental area oxyto-
cin inﬂuences sexualmotivation and sexual behavior by acting directly on
mesolimbic and mesocortical dopaminergic neurons, which play a key
role in motivational and rewarding processes (see Melis et al., 2007;
Melis and Argiolas, 2011; Argiolas and Melis, 2013).
Interestingly, evidence for a role of oxytocin in themodulation of lo-
comotor activity has been also suggested by several studies (Crine et al.,
1983; Uvnäs-Moberg et al., 1994; Klenerova et al., 2009). Accordingly,
low doses of oxytocin given intraperitoneally induced hyperactivity ap-
parently mediated by an anxiolytic effect, while higher doses exerted a
sedative effect. However, in these studies the experimental conditions
were chosen in order to investigate the anxiolytic effects of oxytocin
rather than a possible role of the neuropeptide in the control of locomo-
tor activity or a possible interactionwith the nigrostriatal dopaminergicthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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this regard, the substantia nigra is a brain area of special interest
since: 1) oxytocinergic ﬁbres and terminals project here from the
paraventricular nucleus of the hypothalamus (Adan et al., 1995; Mai
et al., 1993; Sofroniew, 1983; Zimmerman et al., 1984); 2) oxytocinergic
receptors and oxytocin receptor messenger RNA are found in the
substantia nigra of the human (Loup et al., 1989, 1991) and rat brain
(Vaccari et al., 1998), respectively; and 3) the pars compacta of the
substantia nigra contains the cell bodies of nigrostriatal dopaminergic
neurons which project to the basal ganglia, hence in circuits playing a
pivotal role in the control of motor activity (see von Bohlen Und
Halbach et al., 2004). Accordingly, the degeneration of dopaminergic
nigrostriatal neurons causes motor disturbances such as those found
in Parkinson's disease (see Hodaie et al., 2007).
During the studies aimed at investigating the effect of oxytocin
injected into the ventral tegmental area on penile erection and sexual
activity (Melis et al., 2007, Succu et al., 2008), oxytocin injected into
the substantia nigra was found unable to induce penile erection; how-
ever it was found able to reduce locomotor activity. This prompted us
to study the effect of oxytocin on locomotor activity and its mechanism
of action when given systemically and into the substantia nigra. In par-
ticular, the effect of low and high doses of oxytocin given intraperitone-
ally (IP) or into the substantia nigra and the effect of d(CH2)5Tyr(Me)2-
Orn8-vasotocin, a selective oxytocin receptor antagonist, given into the
lateral ventricles (ICV) or the substantia nigra, on locomotor activity
were studied in male rats habituated to the experimental conditions
(in order to avoid the anxiety status induced by novelty). Moreover,
the presence of nigral oxytocinergic ﬁbres and their localizationwith re-
spect to nigral neurons immunoreactive for tyrosine hydroxylase (TH)
(amarker of dopaminergic neurons)was investigated by immunohisto-
chemistry. Finally, the effect of oxytocin-saporin (OXY-SAP), a recently
discovered neurotoxin that speciﬁcally destroys neurons presenting
oxytocinergic receptors on their surface (Baskin et al., 2010), injected
bilaterally into the substantia nigra, on spontaneous locomotor activity
was studied. Together, the results of the above experimentswith oxyto-
cin, d(CH2)5Tyr(Me)2-Orn8-vasotocin and with OXY-SAP, which re-
vealed the existence of a correlation between the changes in
locomotor activity found in OXY-SAP-treated rats and the extent of
the changes in nigral TH and vesicular glutamate transporters
(VGluT1, VGluT2 and VGluT3) immunoreactivity (IR) measured at
28 days after OXY-SAP, provide support for a modulatory role of oxyto-
cin on locomotor activity at the level of the substantia nigra.
Materials and methods
Animals
Male Sprague Dawley rats (250–300 g at the beginning of the exper-
iments)were obtained fromHarlanNossan (Correzzana, Italy). Animals
were kept 4 per cage (38 cm × 60 cm × 20 cm) and were acclimated to
the housing facilities of the Department of Biomedical Sciences of the
University of Cagliari for at least 10 days before the beginning of the ex-
periments under controlled environmental conditions (24 °C, 60% hu-
midity, 12 h light/dark cycle, with lights on from 08:00 to 20:00 h)
and with water and standard laboratory food ad libitum. The experi-
ments were performed between 10:00–14:00 h accordingly to the
guidelines of the European Communities Directive of September 22,
2010 (2010/63/EU) and the Italian Legislation (D.L. March 4, 2014, n.
26), and approved by the Ethical Committee for Animal Experimenta-
tion of the University of Cagliari.
Drugs and peptides
Oxytocin was purchased from Sigma-Aldrich (S. Louis, MO, USA);
d(CH2)5Tyr(Me)2-Orn8-vasotocin from Bachem AG (Bubendorf, CH).
Oxytocin-saporin coniugated (OXY-SAP) and Blank-saporin coniugated(BLANK-SAP) from Advanced Targeting Systems (Bemmel, The
Netherlands). All other reagents were from available commercial
sources.
Systemic treatments
Oxytocin (0.5, 50 and 2000 μg) or saline alonewas given to rats IP in
a volume of 3 mL/kg of rat body weight.
Microinjections into the substantia nigra and into the lateral ventricles
For microinjections into the substantia nigra or ICV, stainless-steel
chronic guide cannulas (22 gauge) aimed bilaterally at the substantia
nigra (coordinates: 5.3 mm posterior, 2.0 mm lateral and 2.0 mm ven-
tral to dura), or unilaterally at the lateral ventricle (coordinates:
1.0 mm posterior, 1.5 mm lateral and 2.0 mm ventral to dura)
(Paxinos and Watson, 2007) were stereotaxically implanted (Stoelting
Co.,WoodDale, IL, USA) in the skull of male rats under isoﬂurane anaes-
thesia (1.5–2%). Rats were given one week to recover from surgery.
Oxytocin dissolved in saline was injected bilaterally (50–200 ng/
site) into the substantia nigra in a volume of 0.3 μL/site. When
d(CH2)5Tyr(Me)2-Orn8-vasotocin was given in combination with oxy-
tocin, it was dissolved in saline and given ICV (2 μg/rat) in a volume of
10 μL 10 min before IP oxytocin (2000 μg/kg) (see above). When
d(CH2)5Tyr(Me)2-Orn8-vasotocin was given alone, ICV or bilaterally
into the substantia nigra, the compound was dissolved in saline and
given ICV at the dose of 10 μg/rat in a volume of 10 μL, or into the
substantia nigra at the dose of 2 μg/site in a volume of 0.3 μL/site. Micro-
injections were performed via an internal cannula (28 gauge), which
extended 6.0 mm and 1.5 mm below the tip of the guide cannula for
substantia nigra and ICV, respectively (Paxinos and Watson, 2007),
and connected by polyethylene tubing to a 10-μL Hamilton syringe
driven by a CMA/100 microinfusion pump (Harvard Apparatus,
Holliston,MA, U.S.A.). Injectionswere performed in twomin at constant
ﬂow rate and after injection the tip of the cannula was left in the injec-
tion site for 30 s to allow the spreading of the injected solution.
Lesioning procedure of the substantia nigra with Oxytocin-saporin (OXY-
SAP)
The day after a prior assessment of spontaneous locomotor activity
(see below), rats were anesthetized with isoﬂurane (1.5–2%), positioned
in a stereotaxic frame (Stoelting Co., Wood Dale, IL, USA) and randomly
injected bilaterally with 0.3 μL of OXY-SAP (60 ng/μL/site), or with the
same amount of BLANK-SAP (60 ng/μL/site) or with vehicle (0.3 μL/site
of phosphate-buffered saline - PBS, pH 7.4). Compoundswere infused bi-
laterally in the substantia nigra (coordinates: 5.3 mm posterior, 2.0 mm
lateral and 8.0 mm ventral to dura) (Paxinos andWatson, 2007) with a
28-gauge Hamilton syringe over a period of 3 min (100 nL/min) per
site. The needle was left in place for an additional 2 min per site to
allow optimal spreading of the neurotoxin. After treatment, rats were
weighed andmonitored daily for general health conditions. Spontaneous
locomotor activity was assessed in each rat other two times, at 14 and
28 days after the injections into the substantia nigra (see below).
Locomotor activity
Before the beginning of the experiments, rats were daily handled for
at least one week to avoid stress due tomanipulation during the exper-
imental sessions. At the end of this period, each rat underwent one ha-
bituation session that lasted for 2 h in order to prevent the inﬂuence of
novelty factors linked to the experimental procedure andmotility appa-
ratus during the experimental sessions. Ratswere individually tested for
motor activity under standardized environmental conditions (in a
soundproof roomwith a light level of 30 lx) with a Digiscan Animal Ac-
tivity Analyzer (Omnitech Electronics, Columbus, Ohio). Each cage
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angles to each other, projecting horizontal infrared beams 2.5 cm apart
and 2 cm above the cage ﬂoor and a further set of 16 horizontal beams
whoseheightwas adapted to the size of the animals (20 cm). Horizontal
and vertical activities were measured as total number of sequential in-
frared beam breaks (counts) in the horizontal or vertical sensors, re-
corded every 5 min, beginning immediately after placing the animals
into the cage, over a period of 30–60min depending on the experiment.
In those experiments in which oxytocin, oxytocin antagonist or saline
was injected directly into the substantia nigra ratswere put into themo-
tility apparatus 10 min after treatment and recording of locomotor ac-
tivity lasted for 60 min; in those experiments in which oxytocin or
saline was given IP (or oxytocin antagonist was given ICV in combina-
tionwith oxytocin or saline given IP) rats were put into themotility ap-
paratus 30 min after IP treatment, and recording of locomotor activity
lasted for 30 min. In those experiments in which locomotor activity
was assessed in substantia nigra OXY-SAP, BLANK-SAP or PBS-injected
rats, the animals were moved from their home cage to the motility ap-
paratus and recording lasted for 30 min.
Histology
In those experiments in which microinjections into the substantia
nigra were performed, rats were sacriﬁced by decapitation immediately
after the experiments, the brains immediately removed and stored in 4%
aqueous formaldehyde for 12–15 days. Forty μm coronal brain sections
were then prepared by means of a freezing microtome, stained with
Neutral Red and inspected on a phase contrast microscope. The position
of the tip of the microinjection cannulas in the substantia nigra was lo-
calized by following the track of bothmicroinjection cannulas through a
series of brain sections (see Fig. 1). In those experiments in which ICV
microinjections were performed, rats were ICV microinjected with
10 μL of methylene blue immediately after the experiments, and then
sacriﬁced by decapitation, the brains immediately removed and visually
inspected in order to ascertain the position of the tip of the injection
cannula into the lateral ventricle. Only those animals found to have
the tip of the injection cannula located correctly into the two
substantiae nigrae or ICV were considered for the statistical evaluation
of the results.
In those experiments in which rats injected with OXY-SAP, BLANK-
SAP or PBS were used, the animals underwent transcardial perfusion
immediately after the experiments, the brains were immediately re-
moved, washed in PBS and stored as described below in theFig. 1. Schematic representation of a coronal section of the rat brain showing the track of
the microinjection cannulas directed to the substantia nigra. The portion of the neutral
red-stained section showing the tips of the two microinjection cannulas in the
substantia nigra (marked by the black arrows) of a rat bilaterally injected with oxytocin
is magniﬁed in the insert. Abbreviations: SN = substantia nigra, VTA = ventral
tegmental area.Immunohistochemistry section. The position of the tip of the needle of
theHamilton syringe into the two substantiae nigraewas veriﬁed as de-
scribed above for rats receiving substantia nigra microinjections by fol-
lowing the track of both microinjections through a few midbrain
sections collected for immunoistochemistry (see above). Only those an-
imals found to have the tip of the injection needle and the lesions lo-
cated correctly into the two substantiae nigrae were considered for
the statistical evaluation of the results.
Immunohistochemistry
Animals were deeply anesthetized with chloral hydrate (400 mg⁄
kg i.p.) and transcardially perfused-ﬁxed with 4% paraformaldehyde in
0.1 M phosphate buffer, pH 7.2–7.4. Brains were rapidly removed;
washed overnight in PBS containing 7% sucrose and 0.01% NaN3, and
orientated in aluminium foil moulds in cryoembedding medium (in g/
L: polyvinyl alcohol, 80; polyethylene glycol, 42.6; Tween-20, 10; and
NaN3, 0.5) (Cocco et al., 2003), and frozen in melting freon (cooled
with liquid nitrogen). Coronal cryosections (10 μm) comprehensive of
the whole substantia nigra obtained from the midbrain (starting from
section with AP≈−6.5 up to section with AP≈−4.5) (Paxinos and
Watson, 2007), were collected onto poly-L-lysine-coated slides and
stored in the vapour phase of a liquid nitrogen tank until used.
For immunohistochemistry aimed at investigating the distribution
of oxytocinergic ﬁbres in the substantia nigra, sections prepared as re-
ported above obtained from6 intact rats,were brought to room temper-
ature and washed in Triton X-100 (1 mL/L, in distilled water). Adjacent
serial sections (10 μm) of the substantia nigrawere then double-labeled
with polyclonal guinea-pig anti-oxytocin (Abcam, Cambridge, UK,
ab51637; 1:400), and polyclonal chicken tyrosine hydroxylase (TH)
(Millipore, Darmstadt, Germany, ab9702; 1:1500), followed by the in-
cubation with the corresponding species-speciﬁc secondary antibodies
conjugated with Cy3 or Alexa-488 (Jackson Immunoresearch Laborato-
ries, West Grove, PA).
Similarly, adjacent serial sections (10 μm) prepared as above, within
±300 μmof the injection site, obtained from rats that received bilateral
injections into the substantia nigra (e.g., PBS, BLANK-SAP or OXY-SAP, 6
rats per group), were selected and alternatively used for single immu-
noﬂuorescence labeling with polyclonal chicken TH (Millipore, Darm-
stadt, Germany) or monoclonal mouse anti-glutamic acid
decarboxylase (GAD) (DSHB, Iowa City, Iowa, USA, GAD-6-c; 1:1500)
or for double immunoﬂuorescence with polyclonal chicken anti-TH
(Millipore, Darmstadt, Germany) and a monoclonal mouse anti-
vesicular glutamate transporter (VGluT) directed against one of the
three isoforms of the vesicular glutamate transporter (VGluT1, VGluT2
or VGluT3, respectively) (NeuroMAB, Davis, CA, USA, 75-066, 75-067,
75-073; 1:300), followed by the incubation with the corresponding
Cy3- or Alexa-488-coniugated species-speciﬁc secondary antibodies.
Primary and secondary antibodies were routinely diluted in PBS con-
taining 30 mL/L of normal donkey serum, 30 mL/L of normal rat serum
and 0.02 g/L NaN3, in order to prevent the non speciﬁc binding. Sections
were ﬁnally washedwith PBS, coverslippedwith PBS-glycerol and visu-
alized using an Olympus BX41/BX51 ﬂuorescence microscope (Milan,
Italy), equipped with a Fuji FinePix S2 and S3 Pro digital camera
(Fujiﬁlm, Milan, Italy). Controls included negative controls (replace-
ment of the primary antibodies by antibody diluent alone) and cross-
reactivity controls (each primary antibody used alone, followed by
each of the appropriate and inappropriate secondary antibody conju-
gates, in turn). In order to obtain a semi-quantitative determination of
the immunoﬂuorescent signal, the FIJI image processing package,
based on ImageJ (NIH) was used. Brieﬂy, 4 animals per group (PBS-,
BLANK-SAP- or OXY-SAP-treated) were randomly selected and 3 sec-
tions per animal within ±300 μm of the injection site were immuno-
stained with each primary antibody (anti-TH, GAD, VGluT1, VGluT2 or
VGluT3; minimum distance of at least 50 μm between sections immu-
nostained with the same primary antibody). For each section, images
Fig. 2. Horizontal and vertical locomotor activity of male rats treated with IP oxytocin: dose-response curves. Rats treated with oxytocin (0.5, 50 and 2000 μg/kg) were put individually
inside the apparatus 30 min after treatment and locomotor activity recorded for 30 min (6 consecutive periods of 5 min) as described in the Materials and methods section. Values are
means ± SEM of the counts of 6 consecutive 5 min periods of 6 rats per group or of the total counts of the entire experiment. *P b 0.05, with respect to saline-treated rats (one- or
two-way ANOVAs followed by Bonferroni's post hoc tests).
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camera (magniﬁcation: 10× for TH and GAD immunostaining; 20×
for VGluTs immunostaining) in order to cover two rectangular areas,
one located medially and the other laterally to a line which allows the
division of the substantia nigra in two equivalent parts, each one com-
prehensive of the whole pars compacta and reticulata. For each rectan-
gular area, the RGB TIFF images were ﬁrst converted to 8-bit grayscale,
then the boundaries of both pars compacta and reticulata where manu-
ally traced by the user and, ﬁnally, background ﬂuorescent signal was
removed by a manual thresholding process. For each section the mean
density was calculated as the sum of the absolute intensities divided
by the sum of the areas of the medial and lateral pars compacta or
reticulata. The values of the three sections where then summed and
the means calculated to obtain pars compacta and reticulata density
values for each animal. The means ± SEM of density values for TH,
GAD, VGluT1, VGluT2 and VGluT3 were then calculated for each group
of experimental animals (PBS-, BLANK-SAP- and OXY-SAP-treated
rats), and changes among groups reported as percent of PBS-treated
rats (PBS IR = 100%).
Statistics
Locomotor activity data are presented either as the horizontal and
vertical counts measured in recordings of consecutive 5 min periods
along the experiment and as the cumulative counts of the same data
in the 30 min (or 60 min) recordings of the entire experiment. These
data were analyzed by one-way ANOVAs along the general factor
“dose” or “treatment” (depending on the experiment) as between sub-
jects factor, or by two-way ANOVAswith the “dose” or “treatment” (de-
pending on the experiment) as between subjects factor and the general
factor “time” (i.e., “5 min periods” or “treatment time”) as within sub-
jects factor.
Statistical analyses of mean density IR values for pars compacta and
reticulata nigral TH, GAD, VGluT1, VGluT2 and VGluT3 IR among groups(PBS, BLANK-SAP and OXY-SAP) were carried out by two-way ANOVAs
performed separately for each of the targets investigated (TH, GAD,
VGluT1, VGluT2 and VGluT3 IR) with the treatment (PBS, BLANK-SAP
or OXY-SAP) as between subjects factor and the sub-portion of the
substantia nigra (compacta or reticulata) as within subjects factor.
F values and associated P, degrees of freedom and eta squared (η2)
values were reported for each of the ANOVA analyses done. To facilitate
reading, η2 were transformed in percentages of the total variance, con-
sidered as 100%. When ANOVAs revealed statistically signiﬁcant main
effects and/or interactions, post hoc pair wise comparisons were per-
formed by using Bonferroni's test. In addition, size effect estimates
(Cohen's d for any signiﬁcant pairwise comparisons)were also reported
in the Results section where appropriate.
ANOVAs and the associated Bonferroni's post-hoc comparisonswere
carried out by using PRISM, Graph Pad 5 Software (San Diego, CA, USA),
with the signiﬁcance level set at P b 0.05. Cohen's dwere calculatedwith
a free online effect size calculator (http://www.campbellcollaboration.
org/escalc/htl/EffectSizeCalculator-SMD1.php).
Results
Effect of IP oxytocin on locomotor activity: dose-response curves and rever-
sal by d(CH2)5Tyr(Me)
2-Orn8-vasotocin
As shown in Fig. 2, IP oxytocin (0.5, 50 and 2000 μg/kg) reduced
dose-dependently both horizontal and vertical locomotor activity in
male Sprague Dawley rats. The effect was observed at the dose of
2000 μg/kg but not at the dose of 0.5 μg/kg or 50 μg/kg, was more pro-
nounced in the ﬁrst 15 min of the test and tended to disappear in the
second 15 min, with motility scores becoming similar to those of
vehicle-treated rats. Accordingly, one-wayANOVAs analyses of horizon-
tal and vertical total counts revealed a signiﬁcant effect of treatment
conﬁrmed by repeated measures two-way ANOVAs analyses of 5 min
periods counts [F(3,100) = 4.79, P b 0.05, η2 = 6.70, and 10.65,
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[F(5,100) = 66.21, P b 0.001, η2 = 54.52, and 42.57, P b 0.001, η2 =
39.74] and a signiﬁcant treatment x periods interaction [F(15,100) =
5.25, P b 0.001, η2=12.98, and 5.04, P b 0.001,η2=14.13] for both hor-
izontal and vertical activity, respectively. Moreover, post hoc compari-
sons revealed highly signiﬁcant differences in both horizontal and
vertical locomotor activity between rats treatedwith 2000 μg/kg oxyto-
cin and saline-treated rats in the ﬁrst three 5min periods [horizontal ac-
tivity: 0–5 min, P b 0.001, d =−3.08, 5–10 min, P b 0.01, d =−1.58;
vertical activity: 0–5 min, P b 0.001, d =−4.43, 5–10 min, P b 0.001,
d =−2.53, 10–15 min, P b 0.01, d =−1.62]. This difference was still
signiﬁcant when considering the total counts of the entire experiment
[totals, P b 0.05, d =−1.49, and P b 0.001, d =−3.38, for horizontal
and vertical activity, respectively] (see Fig. 2 for single points of statisti-
cal signiﬁcance).
As shown in Fig. 3, the inhibitory effect on both horizontal and vertical
locomotor activity induced by oxytocin given IP at the dose of 2000 μg/kg
was completely abolished by the prior treatment of the ratswith the oxy-
tocin receptor antagonist d(CH2)5Tyr(Me)2-Orn8-vasotocin (2 μg/rat ICV
10 min before IP oxytocin). This dose of the oxytocin receptor antagonist
was ineffective on basal motor activity levels. Accordingly, one-way
ANOVAs analyses of horizontal and vertical total counts revealed a signif-
icant effect of treatment conﬁrmed by repeated measures two-way
ANOVAs analyses of the 5 min periods counts (F(3,100) = 5.19,
P b 0.01, η2 = 5.71, and 7.71, P b 0.01, η2 = 12.33], which revealed also
a signiﬁcant effect of periods (F(5,100) = 70.41, P b 0.001, η2 = 54.50,
and 19.49, P b 0.001, η2 = 31.22] and a signiﬁcant treatment x periods
interaction (F(15,100) = 7.32, P b 0.001, η2 = 17.00, and 2.86,
P b 0.001, η2 = 13.77] for both horizontal and vertical activity. Finally,
post hoc comparisons revealed signiﬁcant differences in both horizontal
and vertical locomotor activity between ICV oxytocin antagonist + IPFig. 3.Reversal by d(CH2)5Tyr(Me)2-Orn8-vasotocin (OA) of the inhibition of horizontal and ver
saline (10 μL) and 10min later with IP oxytocin (2000 μg/kg) or saline. After 30min rats were p
the legend of Fig. 2. Values aremeans± SEMof the counts of 6 consecutive 5min periods of 6 ra
treated rats; #P b 0.05, ICV OA + IP Oxy with respect to ICV saline + IP Oxy (one- or two-wayoxytocin- and ICV saline + IP oxytocin-treated rats (periods, horizontal
activity: 0–5 min, P b 0.001, d = 2.64, 5–10 min, P b 0.05, d= 1.39, 10–
15 min, P b 0.05, d = 1.83; vertical activity: 0–5 min, P b 0.001, d =
3.94, 5–10 min, P b 0.01, d = 1.96, 10–15 min, P b 0.05, d= 1.22; totals,
P b 0.05, d = 1.76, and P b 0.01, d = 3.52, for horizontal and vertical
locomotor activity, respectively) while no signiﬁcant differences were
found between ICV oxytocin antagonist + IP oxytocin or IP saline-
treated rats and ICV saline + IP saline-treated rats (periods, totals, all
P N 0.05) (see Fig. 3 for single points of statistical signiﬁcance).
Effect of oxytocin given bilaterally into the substantia nigra on locomotor
activity: dose-response curves
As shown in Fig. 4 oxytocin dose-dependently reduced both hori-
zontal and vertical locomotor activity when injected bilaterally (50,
100 and 200 ng/injection site) into the substantia nigra of male Sprague
Dawley rats. The effect was immediately evident and lasted for the ﬁrst
25–30min. After this period, the reduction of activity in vehicle-treated
rats led the different groups of rats to show very similar motility scores,
thus making impossible to estimate differences between them. Accord-
ingly, two-way ANOVAs analyses of horizontal and vertical cumulative
counts and of 5 min periods counts revealed a signiﬁcant effect of treat-
ment [F(3,220) = 3.93, P b 0.05, η2 = 4.17, and 9.82, P b 0.001, η2 =
12.92] and time [periods, F(11,220) = 101.2, P b 0.001, η2 = 65.77,
and 25.82, P b 0.001, η2 = 31.65; totals: F(2,40) = 188.6, η2 = 48.50,
and 57.7, P b 0.001,η2=18.12] and a signiﬁcant treatment× time inter-
action [periods, F(33,220) = 5.11, P b 0.001, η2 = 9.98, and 6.02,
P b 0.001, η2 = 22.16; totals: F(6,40) = 9.94, P b 0.001, η2 = 7.67,
and 15.69, P b 0.001, η2 = 14.77] for both horizontal and vertical activ-
ity. Post hoc tests revealed that rats treatedwith oxytocin at the doses of
100 and 200 ng had highly signiﬁcant different values in horizontal andtical locomotor activity induced by IP oxytocin. Ratswere treated ﬁrst with ICVOA (2 μg) or
ut individually in the apparatus and locomotor activity recorded for 30min as described in
ts per group or of the total counts of the entire experiment. *Pb 0.05,with respect to saline-
ANOVAs followed by Bonferroni's post hoc tests).
Fig. 4.Horizontal and vertical locomotor activity of rats after bilateral injection of oxytocin into the substantia nigra: dose-response curves. Ratswere bilaterally injected into the substantia
nigrawith oxytocin (50–200 ng/site) or saline (0.3 μL/site) and after 10min put individually in the apparatus and locomotor activity recorded for 60min (12 consecutive periods of 5min)
as described in the legend of Fig. 2. Values aremeans± SEM of the counts of 12 consecutive 5min periods of 6 rats per group or of the counts of the ﬁrst and second 30min periods and of
the entire experiment. *P b 0.05, with respect to saline-treated rats (two-way ANOVAs followed by Bonferroni's post hoc test).
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all 5 min periods in the ﬁrst 20–25 min of the test [periods, saline vs
100 ng, horizontal activity: 0–5 min, P b 0.001, d =−1.79; 5–10 min,
P b 0.001, d = −3.80; 10–15 min, P b 0.05, d = −1.38; 15–20 min,
P b 0.05, d=−1.12; 20–25 min, P b 0.05, d =−1.43; vertical activity:
0–5 min, P b 0.001, d =−3.67; 5–10 min, P b 0.001, d =−1.93; 10–
15 min, P b 0.01, d = −1.76; 15–20 min, P b 0.05, d = −1.16; 20–
25 min, P b 0.01, d =−1.15; saline vs 200 ng, horizontal activity: 0–
5 min, P b 0.001, d = −2.09; 5–10 min, P b 0.01, d = −1.91; 10–
15 min, P b 0.001, d = −1.89; vertical activity: 0–5 min, P b 0.001,
d = −2.76; 5–10 min, P b 0.001, d = −1.76; 10–15 min, P b 0.001,
d = −2.01; 20–25 min, P b 0.01, d = −1.15]. However, oxytocin
inhibited both horizontal and vertical locomotor activity already at the
dose of 50 ng/injection site/rat (totals, 50 ng vs saline: P b 0.01,
d =−1.32, and P b 0.001, d =−1.53, for horizontal and vertical activ-
ity, respectively], although the inhibitory effect of 50 ng of oxytocin on
horizontal activity, at variance from the doses of 100 and 200 ng, was
detectable only 10 min after the beginning of the test [periods, 5–
10 min, P b 0.001, d =−3.45]. Nonetheless, this dose showed an efﬁ-
cacy similar to that of the higher ones in inhibiting total horizontal activ-
ity in the ﬁrst 30 min (totals, all P N 0.05 when comparing the three
doses tested). Finally, no signiﬁcant differences were observed among
the 4 treatment groups in the values of both horizontal and vertical lo-
comotor activity of the second 30min (totals, all P N 0.05) (see Fig. 4 for
single points of statistical signiﬁcance).
Effect of d(CH2)5Tyr(Me)
2-Orn8-vasotocin given bilaterally into the
substantia nigra on locomotor activity
As shown in Fig. 5, d(CH2)5Tyr(Me)2-Orn8-vasotocin injected bilat-
erally into the substantia nigra at the dose of 2 μg/injection site in-
creased both horizontal and vertical locomotor activity by about 50%
and 75% respectively, when compared to saline-treated rats. Similarresults were found when the compound was injected ICV at the dose
of 10 μg. In both experimental conditions, the effect was immediately
evident and signiﬁcant in the ﬁrst 5–10 min, thereafter disappearing
along the test; however, this difference was still signiﬁcant when com-
paring the total counts values of the entire experiment. Accordingly,
one-way ANOVAs analyses of horizontal and vertical total counts re-
vealed a signiﬁcant effect of treatment conﬁrmed by repeatedmeasures
two-way ANOVAs analyses of the 5 min periods counts [F(3,100) =
3.80, P b 0.05, η2 = 6.28 and 5.00, P b 0.01, η2 = 7.67] which revealed
also a signiﬁcant effect of periods [F(5,100) = 59.78, P b 0.001, η2 =
60.91, and 52.36, P b 0.001, η2 = 57.50] for both horizontal and vertical
activity. Moreover, post hoc comparisons revealed that rats treated ICV
with d(CH2)5Tyr(Me)2-Orn8-vasotocin did not differ from those
injected with the antagonist directly into the substantia nigra (all
P N 0.05) (see Fig. 5 for single points of statistical signiﬁcance).
Effect of Oxytocin-saporin (OXY-SAP) injected bilaterally into the
substantia nigra on locomotor activity: comparison with BLANK-SAP and
PBS
As shown in Fig. 6, Sprague Dawleymale rats bilaterally injected into
the substantia nigra with OXY-SAP (0.3 μL/site, 60 ng/μL) showed a
higher horizontal (by about 50%) and vertical locomotor activity com-
pared to BLANK-SAP- (0.3 μL/site, 60 ng/μL) and PBS- (0.3 μL/site)
injected animalswhen tested for locomotor activity 28 days after the in-
jection [two-way ANOVAs of 5 min periods data, horizontal activity:
treatment, F(2,75) = 16.30, P b 0.001, η2 = 16.73, periods, F(5,75) =
72.94, P b 0.001, η2 = 60.25, treatment x periods, F(10,75) = 1.77,
P N 0.05, η2 = 2.93; vertical activity, treatment, F(2,75) = 2.84,
P N 0.05, η2 = 6.79, periods, F(5,75) = 32.21, P b 0.001, η2 = 47.07,
treatment x periods, F(10,75) = 2.16, P b 0.05, η2 = 6.33]. Augmented
horizontal, but not vertical, locomotor activity valueswere also found in
OXY-SAP-injected rats 28 days after treatment when compared to the
Fig. 5.Horizontal and vertical locomotor activity of rats treatedwith d(CH2)5Tyr(Me)2-Orn8-vasotocin (OA) injected ICV or bilaterally into the substantia nigra. Rats were injectedwith OA
(10 μg) or saline (10 μL) ICV or bilaterally into the substantia nigra (2 μg/site) or saline (0.3 μL/site). After 10min ratswere put individually in the apparatus and locomotor activity recorded
for 30min (6 consecutive fractions of 5min) as described in the legend of Fig. 2. Values aremeans± SEMof the counts of 6 consecutive 5min periods of 6 rats per group or of the counts of
the entire experiment. *P b 0.05, with respect to saline-treated rats (one- or two-way ANOVAs followed by Bonferroni's post hoc tests).
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after) the OXY-SAP injection [two-way ANOVAs of 5 min periods data,
horizontal activity, treatment time, F(2,75) = 7.67, P b 0.01, η2 =
9.71, periods F(5,75) = 51.48, P b 0.001, η2 = 59.98, treatment time x
periods, F(10,75)=1.43, P N 0.05,η2=3.34; vertical activity, treatment
time, F(2,75) = 1.59, P N 0.05, η2 = 2.45; periods, F(5,75) = 21.51,
P b 0.001, η2 = 47.49, treatment time x periods, F(10,75) = 1.21,
P N 0.05, η2 = 5.36].
The above results were further conﬁrmed by two-way ANOVAs of
the total motor activity data [horizontal activity, treatment,
F(2,30) = 2.21, P N 0.05, η2 = 13.16, treatment time, F(2,30) =
1.14, P N 0.05, η2 = 1.80, treatment × treatment time, F(4,30) =
5.40, P b 0.01, η2 = 16.96; vertical activity, treatment, F(2,30) =
0.71, P N 0.05, η2 = 4.52, treatment time, F(2,30) = 6.20, P b 0.01,
η2 = 12.27, treatment x treatment time, F(4,30) = 1.60, P N 0.05,
η2 = 6.36]. Accordingly, a higher horizontal locomotor activity was
observed in OXY-SAP-injected rats compared to BLANK-SAP- and
PBS-injected animals 28 days [OXY-SAP vs PBS, P b 0.001, d = 2.99;
OXY-SAP vs BLANK-SAP, P b 0.05, d = 3.54], but not before or
14 days after the treatment [all P N 0.05], while no signiﬁcant differ-
ences were observed in horizontal activity between BLANK-SAP- and
PBS-injected animals before, 14 and 28 days after the treatment [all
P N 0.05]. Post-hoc tests revealed also that BLANK-SAP and PBS-
injected rats showed also a marked tendency of the values of vertical
activity to decrease along the tests. Accordingly, in PBS-injected rats
these values were found signiﬁcantly lower at 28 days after
treatment when compared with those obtained from the same
group before treatment [P b 0.05, d = −1.27] and with those ob-
tained at the same time from the OXY-SAP- but not BLANK-SAP-
injected rats [P b 0.05, d = 1.42 and P N 0.05, respectively].
Immunohistochemistry
As expected, TH IR was found mainly in neuronal perykaria of the
substantia nigra pars compacta and, to a lesser extent, in the pars
reticulata (Fig. 7a, d). In the pars compacta, a diffuse network ofoxytocin-immunoreactive ﬁbres (Fig. 7b, e) approaching to and imping-
ing onto TH immunoreactive perykaria and running close to TH immu-
noreactive dendrites as well, was also found (Fig. 7c, f). Twenty eight
days after treatment, bilateral injections of OXY-SAP in the substantia
nigra caused a marked decrease in the number of TH immunoreactive
perykaria in the substantia nigra and in their dendrites coursing into
the substantia nigra pars reticulata when compared to bilateral
BLANK-SAP, which also caused in a few cases a very modest reduction
(≈10%) in TH IR when compared to bilateral PBS injections, considered
as controls (TH IR valu = 100%) (Fig. 8e, c, a, respectively). The reduc-
tion of TH IR in OXY-SAP-treated rats vs BLANK-SAP- and PBS-treated
rats was found in the substantia nigra for about 300 μm around the
injection sites in all the sections analyzed and was more evident in
the pars reticulata (≈90%) than in the pars compacta (≈50%) of
the substantia nigra [two-way ANOVA, treatment, F(2,9) = 9.78,
P b 0.01, η2 = 20.89, compacta/reticulata, F(1,9) = 194.0,
P b 0.001, η2 = 65.43, treatment x compacta/reticulata, F(2,9) =
1.52, P N 0.05, η2 = 1.03; post hoc tests: compacta, OXY-SAP vs
PBS, P b 0.01, d = −2.12; OXY-SAP vs BLANK-SAP, P b 0.01,
d = −2.11; reticulata, OXY-SAP vs PBS, P b 0.05, d=−3.78; OXY-SAP
vs BLANK-SAP, P b 0.05, d=−4.13].
In contrast, no change was found to occur in GAD IR in the entire
susbtantia nigra (pars compacta and reticulata) of OXY-SAP treated
rats when compared to BLANK-SAP- or PBS-treated control rats (Fig.
8f, d, b, respectively) [two-way ANOVA, treatment, F(2,9) = 0.69,
P N 0.05, η2 = 1.75, compacta/reticulata, F(1,9) = 245.5, P b 0.001,
η2 = 82.62, treatment x compacta/reticulata, F(2,9) = 1.84, P N 0.05,
η2 = 1.24; post hoc tests: all P N 0.05].
The decrease in TH IR found in OXY-SAP treated rats was parallel
with a concomitant marked decrease in VGluT1 IR in the substantia
nigra pars reticulata (≈75%) and in the substantia nigra pars compacta
(≈73%) (Fig. 9h), and of both VGluT2 (Fig. 10h) and VGluT3 (Fig. 11h)
(N90% for both VGluT2 and VGluT3 in pars compacta and ≈90% for
VGluT2 and 70% for VGluT3 in pars reticulata) in either the substantia
nigra pars compacta and reticulata, with minimal residual VGluT3
IR and almost no residual VGluT2 IR in both areas. The decrease in the
Fig. 6. Horizontal and vertical locomotor activity of rats bilaterally injected with Oxytocin-saporin (OXY-SAP) into the substantia nigra. Rats received OXY-SAP (0.3 μL/site, 60 ng/μL) or
BLANK-SAP (0.3 μL/site, 60 ng/μL) or PBS (0.3 μL/site). Locomotor activity was assessed before (pre-lesion), 14 (two weeks) and 28 days after the treatment. Rats were put individually
in the apparatus and locomotor activity recorded for 30 min (6 consecutive periods of 5 min). Values are means ± SEM of the counts of 6 consecutive 5 min periods of 6 rats per
group or of the total counts of the entire experiment. *P b 0.05, with respect to the corresponding group of PBS-treated rats; #P b 0.05, with respect to the corresponding group of
BLANK–SAP-injected rats; §P b 0.05, with respect the corresponding pre-lesion values (two-way ANOVAs followed by Bonferroni's post hoc tests).
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compared to BLANK-SAP–treated rats (Fig. 9e), in which only a very
small decrease (≈15%) in this transporter was found in either
substantia nigra pars compacta and reticulata when compared to PBS-
treated rats (Fig. 9b), as found for TH IR [two-way ANOVA, VGluT1 IR,treatment, F(2,9) = 6.77, P b 0.05, η2 = 17.81, compacta/reticulata,
F(1,9) = 55.89, P b 0.001, η2 = 51.77, treatment x compacta/reticulata,
F(2,9) = 5.52, P b 0.05, η2 = 10.24; post hoc tests: compacta, OXY-SAP
vs PBS, P b 0.001, d = −2.82; OXY-SAP vs BLANK-SAP, P b 0.01,
d=−1.92; reticulata, OXY-SAP vs PBS, P b 0.05, d=−5.57].
Fig. 7. Substantia Nigra (AP=−5.40 approximately, sections adjacent to the site used for microinjections) immunostained for Tyrosine Hydroxylase (TH, Alexa-488: green labeling) and
oxytocin (Cy3: red labeling). Oxytocin ﬁbres were observed almost exclusively in the Substantia Nigra pars compacta and were more abundant in its central portion (a, b and c). Fibres
were mainly distributed dorsally and within the pars compacta, where they run close to dopaminergic dendrites and perikarya (d, e and f). e and f: magniﬁcation showing an
oxytocinergic ﬁbre impinging (arrowheads in e and f) on the perikaryon of a dopaminergic neuron of the pars compacta. SNc: substantia nigra pars compacta; SNr: substantia nigra
pars reticulata. a, b and c, scale bar = 100 μm; d, e and f, scale bar = 25 μm.
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VGluT2 IR (Fig. 10e) andVGluT3 IR (Fig. 11e)were signiﬁcantly reduced
in both the substantia nigra pars compacta (both by ≈46%) and
reticulata (VGluT2 by ≈39% and VGluT3 by ≈31%) when compared
to PBS-treated rats (Fig. 10b and 11b, respectively) [two-way ANOVA,
VGluT2 IR, treatment, F(2,9) = 25.90, P b 0.001, η2 = 50.12,
compacta/reticulata, F(1,9) = 64.34, P b 0.001, η2 = 24.0, treatment x
compacta/reticulata, F(2,9) = 18.52, P b 0.001, η2 = 13.82; post hoc
tests: compacta, OXY-SAP vs PBS, P b 0.001, d = −6.49, BLANK-SAP
vs PBS, P b 0.001, d = −2.02, OXY-SAP vs BLANK-SAP, P b 0.001,
d =−2.64; reticulata, OXY-SAP vs PBS, P b 0.05, d =−5.59; VGluT3
IR, treatment, F(2,9) = 16.69, P b 0.001, η2 = 46.82, compacta/
reticulata, F(1,9) = 54.50, P b 0.001, η2 = 20.72, treatment x
compacta/reticulata, F(2,9) = 21.57, P b 0.001, η2 = 16.41; post hoc
tests: compacta, OXY-SAP vs PBS, P b 0.001, d = −4.86, BLANK-SAP
vs PBS, P b 0.01, d = −1.78, OXY-SAP vs BLANK-SAP, P b 0.01,
d=−2.57; reticulata, OXY-SAP vs PBS, P b 0.05, d=−4.09].
Discussion
The present study conﬁrms and extends the results of previous stud-
ies suggesting that oxytocin is involved in the control of locomotor ac-
tivity (Klenerova et al., 2009; Uvnäs-Moberg et al.,1994, Maejima
et al., 2015). In particular our results conﬁrm that oxytocin decreases lo-
comotor activity of male rats in a non-novelty paradigm when given IP
at high doses (2mg/kg), but not at doses up to 0.05 mg/kg, which were
found ineffective when compared to vehicle-treated control rats. The
failure of low doses of oxytocin given IP to inﬂuence motility is in con-
trast with the results of above studies, which reported that low dosesof oxytocin similar to those used in this study given IP increasedmotility
(Klenerova et al., 2009; Uvnäs-Moberg et al., 1994). This discrepancy
may be due to the reduction of anxiety levels secondary to the use in
the present study of a non-novelty experimental paradigm, which
would reduce anxiety and thus the anxiolytic effect of oxytocin, appar-
ently responsible for the increased locomotor activity induced by low
doses of the neuropeptide in the above studies (see Introduction).
Nonetheless, the inhibitory effect of high doses of oxytocin on locomo-
tor activity is apparently mediated by the stimulation of central
oxytocinergic receptors, being completely antagonized by the selective
oxytocin receptor antagonist d(CH2)5Tyr(Me)2-Orn8-vasotocin given
ICV (Bankowski et al., 1980) at a dose whichwas ineffective on locomo-
tor activity. These results are also similar to those of a previous study
showing that rats treated with oxytocin given IP at the dose of 0.1 and
1.0 mg/kg or ICV at the dose of 2 and 20 ng showed a reduced explor-
atory activity in the periphery of and shift their activity to the centre
of the arena of the openﬁeld apparatus, and that the reduction in the ex-
ploratory behavior was antagonized by an oxytocin receptor antagonist
injected either IP or ICV, at doseswhichper se did not induce any behav-
ioral effect (Uvnäs-Moberg et al., 1992).
In agreementwith a central effect of oxytocin in reducing locomotor
activity, the present study also shows for the ﬁrst time that oxytocin
injected bilaterally into the substantia nigra reduced locomotor activity
in a dose-dependent manner. The ﬁnding suggests that the substantia
nigra may be one of the brain areas where systemic oxytocin acts to in-
hibit locomotor activity. In line with this hypothesis, the bilateral injec-
tion of d(CH2)5Tyr(Me)2-Orn8-vasotocin in the substantia nigra at the
dose of 2 μg/site caused an increase of locomotor activity. Together the
above ﬁndings suggest the existence of a tonic active inhibitory role of
Fig. 8. Coronal sections of the Substantia Nigra (AP =−5.30 approximately, adjacent to the site used for microinjections) immunostained for Tyrosine Hydroxylase (TH) and Glutamic
Acid Decarboxylase (GAD) of rats injected with PBS (a and b, respectively), BLANK-SAP (c and d, respectively) and OXY-SAP (e and f, respectively) at 28 days after treatment. OXY-SAP
induced a reduction in TH IR both in the perikarya of the pars compacta and in their dendrites coursing into the pars reticulata whereas BLANK-SAP induced no TH IR reduction or
only a modest reduction, mainly in the pars reticulata, when compared to PBS. No evident reduction in GAD IR was observed when comparing BLANK-SAP- and OXY-SAP- to PBS-
injected animals (d, f and b respectively). Scale bar = 1 mm.
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nigra.
As to themechanismbymeans ofwhich oxytocin decreases locomo-
tor activity by acting at the level of the substantia nigra, onepossibility is
that oxytocin reduces the activity of nigrostriatal dopaminergic system.
Such a reduction may be mediated by the stimulation of oxytocinergic
receptors localized 1) in the cell bodies and dendrites of nigrostriatal
dopaminergic neurons, or 2) in other neurons present in the substantia
nigra that may interfere directly or indirectly with the activity of the
nigrostriatal dopaminergic system. Accordingly, dopaminergic neurons
originating in the substantia nigra pars compacta and projecting to
striatal neurons, play a pivotal role in the initiation of movement and
in its expression (see Björklund and Dunnett, 2007, and references
therein)(Fig. 12). Indeed, 1) striatal neurons send inhibitory projections
not only to the (internal) globus pallidus and the entopeduncular nu-
cleus but also to the pars reticulata and compacta of the substantia
nigra (Costall et al., 1972; Marshall and Ungerstedt, 1977; Hauber,
1998; Radnikow and Misgeld, 1998); and 2) the substantia nigra pars
reticulata contains also cell bodies of neurons which project to different
brain areas important for postural muscle tone and locomotion initia-
tion and execution, i.e., the superior colliculus, the pedunculopontine
nucleus and the thalamus. The striatal inhibitory projections to the
globus pallidus and the substantia nigra pars reticulata are part of the
so-called direct pathway, while those projecting to the entopeduncular
nucleus (external globus pallidus in humans) are part of the so-called
indirect pathway (for a review see Takakusaki et al., 2003 and Hauber,
1998) (see also Fig. 12).
In line with studies showing that oxytocin receptors and oxytocin
receptor RNA messenger are present in the substantia nigra pars
compacta (Loup et al., 1989, 1991; Vaccari et al., 1998) and with thepossibility that oxytocin decreases locomotor activity by stimulating
oxytocin receptors localized in the cell bodies and dendrites of
nigrostriatal dopaminergic neurons, this study also shows that oxytocin
immunoreactive ﬁbres are diffuse in the substantia nigra pars compacta
running close to and impinging often onto the cell bodies of TH immu-
noreactive (e.g., dopaminergic) neuronspresent in this brain area.How-
ever, the possibility that the decreased motility induced by oxytocin is
secondary to a reduction of the activity of nigrostriatal dopaminergic
neurons caused by the stimulation of oxytocinergic receptors localized
in the cell bodies of these neurons, is unlikely. Indeed several lines of ev-
idence show that oxytocin facilitates rather than inhibit the activity of
dopaminergic neurons, for instance when injected into the ventral teg-
mental area, where the neuropeptide was found able to induce penile
erection, an effect that occurred concomitantly to an increased dopa-
mine release in the nucleus accumbens and in themedial prefrontal cor-
tex (see Melis et al., 2007; Sanna et al., 2012). Thus, it appears more
likely that the decrease in locomotor activity induced by intranigral oxy-
tocin is mediated by other mechanisms rather than by the direct inhibi-
tion of nigrostriatal dopaminergic neurons. For instance, oxytocin may
act on oxytocin receptors localized in other neurons present in the
substantia nigra that may interfere directly or indirectly with the activ-
ity of the nigrostriatal dopaminergic system, i.e., by modulating the ac-
tivity of excitatory amino acid (glutamatergic) synapses that activate
nigrostriatal dopaminergic neurons, or of GABAergic synapses that in-
hibit glutamatergic synapses impinging on nigrostriatal dopaminergic
neurons, in both cases through the stimulation of presynaptic
oxytocinergic receptors localized in these synapses. Alternatively, oxy-
tocin may directly facilitate the activity of glutamatergic synapses that
impinge on GABAergic neurons projecting from the substantia nigra
pars reticulata to the thalamus (and other nuclei of the brainstem,
Fig. 9. Substantia Nigra (AP =−5.30 approximately, sections adjacent to the site used for microinjections) immunostained for Tyrosine Hydroxylase (TH, Cy3: red labeling), Vesicular
Glutamate Transporter 1 (VGluT1, Alexa-488: green labeling) and merged IR of rats injected bilaterally into the substantia nigra with PBS (a, b and c, respectively), BLANK-SAP (d, e
and f, respectively) and OXY-SAP (g, h and i, respectively) at 28 days after treatment. In PBS-injected animals, VGluT1 (b) was expressed in both pars compacta (SNc) and reticulata
(SNr), with a higher density in SNc. After 28 days, BLANK-SAP induced no VGluT1 IR reduction (e), except for a slight decrease observable mainly in SNr in the presence of a parallel
TH IR reduction. OXY-SAP induced a reduction in VGluT1 IR (h), which was very similar in the SNr and in the SNc, with a parallelism between the extent of TH IR reduction and
VGluT1 IR decrease [higher levels of VGluT1 IR corresponded to higher levels of TH IR (big arrowheads in g and h) and vice versa (small arrowheads in g and h)]. Scale bar = 100 μm.
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which play amain role in the control of locomotor activity. The presence
of such stimulatory and inhibitory synapses in the substantia nigra,
which modulate the activity of nigrostriatal dopaminergic neurons
and of GABAergic neurons projecting to the thalamus (and other nuclei
of the basal ganglia) is well documented (Hauber, 1998; Kaneda et al.,
2005; Windels and Kiyatkin, 2006; Lee et al., 2013; Morales and Root,
2014). The mechanisms recalled above may be not mutually exclusive,
contributing all to determine the ﬁnal activity of nigrostriatal dopami-
nergic neurons and nigrothalamic GABAergic neurons (Fig. 12).
Support for a role of oxytocin receptors located in neurons different
from the cell bodies of nigrostriatal dopaminergic neurons, possibly pre-
synaptically in glutamatergic nerve endings, in the control of locomotor
activity is provided by the increase found in the spontaneous locomotor
activity of male rats bilaterally injected with OXY-SAP, a neurotoxin
characterized for its ability to destroy neurons presenting oxytocinreceptors on their surface (Baskin et al., 2010).This increase was very
evident 28 days after OXY-SAP treatment, when compared with the lo-
comotor activity of control rats injected bilaterally with an equimolar
amount of a control mock peptide-saporin conjugate (BLANK-SAP) or
with an equal volume of PBS (motility scores, OXY-SAP N BLANK-
SAP≈ PBS). Indeed, the increase in spontaneous locomotor activity in
OXY-SAP-treated rats occurred concomitantly to a marked reduction
not only in TH IR in the substantia nigra pars compacta, but also of
VGluT1 IR, VGluT2 IR and VGluT3 IR in either the substantia nigra pars
compacta and reticulata, although with some difference among them,
and no change in GAD IR in both the substantia nigra pars compacta
and reticulata. In fact, the marked destruction of nigral dopaminergic
neurons (revealed by the reduction in TH IR) and of nigral (local, effer-
ent or afferent) glutamatergic neurons (revealed by the reduction of the
IR of all three VGlu transporters)(see Fremeau et al., 2004; Martín-
Ibañez et al., 2006; Antal et al., 2014); with no reduction in GABAergic
Fig. 10. Substantia Nigra (AP =−5.30 approximately, sections adjacent to the site used for microinjections) immunostained for Tyrosine Hydroxylase (TH, Cy3: red labeling), Vesicular
Glutamate Transporter 2 (VGluT2, Alexa-488: green labeling) andmerged IR of rats injected bilaterally into the substantia nigra with PBS (a, b and c, respectively), BLANK-SAP (d, e and f,
respectively) andOXY-SAP (g, h and i, respectively) at 28 days after treatment. In PBS-injected animals, VGluT2 (b)was expressed in both pars compacta (SNc) and reticulata (SNr), with a
slightly higher density in SNc. After 28 days OXY-SAP induced an almost complete reduction in VGluT2 IR in SNr and SNc (h) with a strong parallelism between the extent of VGluT2
decrease and TH IR reduction (g). BLANK-SAP also reduced VGluT2 IR in both SNr and SNc (e) but much less than OXY-SAP and with onlyminor effects on TH IR (d). Scale bar= 100 μm.
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treated rats, suggests that oxytocinergic receptors are present in the
substantia nigra in dopaminergic and in glutamatergic neurons as
well, while they apparently are not present in nigral GABAergic neu-
rons. Since the destruction of the nigral neurons bearing oxytocin recep-
tors causes an increase in spontaneous locomotor activity, and the
destruction of nigrostriatal dopaminergic neurons alone would be ex-
pected to cause a decrease rather than an increase in locomotor activity
[as found for instance after the bilateral injection of the selective cate-
cholaminergic neurotoxin 6-hydroxy-dopamine (6-OH-DA) into the
substantia nigra, i.e., see Grieb et al., 2013], together these ﬁndings sup-
port the hypothesis that the increased locomotor activity found in OXY-
SAP-treated rats is mediated by changes in the activity of nigral gluta-
matergic rather than nigrostriatal dopaminergic neurons. Accordingly,
it is well known that the destruction of nigrostriatal dopaminergic neu-
rons (for instance by 6-OHDA) reduces the activity of striatal GABAergic
neuronal efferents and increases the activity of glutamatergic neuronsoriginating mainly in the subthalamic nucleus (but also in other brain
areas such as the superior colliculus, the pedunculopontine nucleus,
the cortex and so on), and impinging on GABAergic neuronal efferences
in the substantia nigra pars reticulata to other nuclei of the basal ganglia
motor system (i.e., the thalamus and other nuclei of the brainstem, in-
cluding the superior colliculus and the pedunculopontine nucleus)
(see Hauber, 1998, Melis and Gale, 1983, 1984a, 1984b; Martín-Ibañez
et al., 2006) (Fig. 12). In these experimental conditions, in which a
nigrostriatal dopamine loss is present, a reduction of glutamatergic
tone in the substantia nigra pars reticulata, obtained for instance with
a selective glutamic acid receptor antagonist injected in the substantia
nigra pars reticulata, facilitates locomotor activity, apparently mediated
by the reduction of the burst ﬁring of pars reticulata nigral GABAergic
efferences, as expected (see Hauber, 1998; Takakusaki et al., 2003;
Kaneda et al., 2005; Windels and Kiyatkin, 2006; Lee et al., 2013;
Morales and Root, 2014 and references therein). A similar experimental
condition may occur in the OXY-SAP-treated rats of this study.
Fig. 11. Substantia Nigra (AP =−5.30 approximately, sections adjacent to the site used for microinjections) immunostained for Tyrosine Hydroxylase (TH, Cy3: red labeling), Vesicular
Glutamate Transporter 3 (VGluT3, Alexa-488: green labeling) andmerged IR of rats injected bilaterally into the substantia nigra with PBS (a, b and c, respectively), BLANK-SAP (d, e and f,
respectively) and OXY-SAP (g, h and i, respectively) at 28 days after treatment. In PBS-injected animals VGluT3 had a perisomatic localizationmainly on dopaminergic neurons of the pars
compacta (SNc) (big arrowheads), whereas in the pars reticulata (SNr) a perisomatic distribution on a few non-dopaminergic neurons was observed (small arrowheads). After 28 days,
OXY-SAP induced an almost complete reduction inVGluT3 IR in both SNr and SNc (h)with a strongparallelismbetween the extent of VGluT3decrease and TH IR reduction (g). BLANK-SAP
also reduced VGluT3 IR in both SNr and SNc (e), but much less than OXY-SAP and with only minor effects on TH IR (d). Scale bar = 100 μm.
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rons originating in the substantia nigra pars compacta destroyed by
OXY-SAP, which has also destroyed glutamatergic nerve terminals of
neurons projecting to the substantia nigra pars reticulata (probably
originating from the subthalamic nucleus, the superior colliculus, the
pedunculopontine nucleus, the frontal cortex and so on) (see Hauber,
1998; Takakusaki et al., 2003; Kaneda et al., 2005; Windels and
Kiyatkin, 2006; Martín-Ibañez et al., 2006; Lee et al., 2013; Morales
and Root, 2014 and references therein). In fact, the destruction of
these glutamatergic neurons should be expected to cause by itself an in-
crease in locomotor activity in intact rats as well as a reduction in the
glutamatergic overtone that decreases the impairment of locomotor ac-
tivity caused by the destruction of nigrostriatal dopaminergic neurons
(as found in 6-hydroxy-dopamine-lesioned rats), thereby leading to
an increase in spontaneous locomotor activity, as found in OXY-SAP-
treated rats.The interpretation given above is complicated in part by the unex-
pected decrease in nigral VGluT2 IR and VGluT3 IR found in BLANK-
SAP-treated rats, in which only a small decrease in VGluT1 IR was de-
tected, as if BLANK-SAP was able to affect selectively neuronal popula-
tions containing VGluT2 IR and VGluT3 IR, but not VGluT1 IR or TH IR,
in spite of the fact that BLANK-SAP is supposed to be devoid of any bio-
logical activity. Although such decreases were not as dramatic as those
found in OXY-SAP-treated rats, they would have been expected to in-
crease basal motor activity in BLANK-SAP-treated rats, at least to some
degree, as found in OXY-SAP-treated rats. In fact, in line with the
above interpretation, BLANK-SAP-induced VGluT2 IR and VGluT3 IR de-
creases indicate some lesioning of glutamatergic afferences to the
substantia nigra, as discussed above for OXY-SAP-treated rats. One rea-
son why basal motor activity was found to be not changed in BLANK-
SAP-treated rats in spite of the reduction in nigral VGluT2 IR and
VGluT3 IR, may be the fact that BLANK-SAP-treated rats present only a
Fig. 12. A hypothetical model that may explain the inhibitory effect of nigral oxytocin on
locomotor activity, in line with the results of this study and the canonical view of basal
ganglia control of motor activity. Brieﬂy, oxytocin acts mainly on receptors localized
presynaptically in the nerve endings of glutamatergic (GLU) neurons originating mainly
in the subthalamic nucleus (STN), and impinging on cell bodies and dendrites of nigral
dopamine (DA) neurons in the substantia nigra pars compacta (SNc) and reticulata
(SNr). Oxytocin receptors (OXY-R) are also present in the cell bodies and dendrites of
DA neurons projecting to the striatum. The stimulation of OXY receptors in GLU nerve
endings causes an increase in nigral GLU tone, which leads to an increase in the tone of
nigral/pallidal (SNr/GPi) GABAergic efferents to the thalamus (and other nuclei of the
basal ganglia). This causes a decrease of the activity of excitatory thalamocortical
projections, leading to a decrease in locomotor activity. The oxytocin-induced inhibition
of locomotor activity does not occur when OXY receptors are blocked by an OXY
receptor antagonist or after the destruction not only of GLU neurons, but also of
nigrostriatal DA neurons bearing OXY receptors by OXY-SAP. Indeed, in these
experimental conditions (e.g. when a marked decrease in nigrostriatal DA activity is
present), a reduction in nigrothalamic GABA activity occurs, leading in turn to an
increase of the activity of thalamocortical projections and of locomotor activity (see
Discussion section for details).
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rats. In fact, this suggests that nigrostriatal dopaminergic neurons are
still active in BLANK-SAP-treated rats. Since the absence of nigrostriatal
dopaminergic neurons is necessary in order to activate the changes in
nigral GABAergic and glutamatergic tone for inﬂuencing motor activity
as discussed above, this may explain why the lesion of nigral gluta-
matergic efferences containing VGluT2 and VGluT3 only, does not mod-
ify basal motor activity in BLANK-SAP-treated rats. Hence, a
concomitant lesion of both dopaminergic and glutamatergic neurons
in the substantia nigra, as it occurs in OXY-SAP-treated rats, seems to
be necessary to increase basal motor activity.
Whatever mechanism is responsible for the reduction of nigral
VGluT2 IR and VGluT3 IR by BLANK-SAP and of the failure of such de-
creases to increase basal motor activity, together the results of this
study show that endogenous oxytocin in the substantia nigramaymod-
ulate locomotor activity by acting on oxytocin receptors localized in glu-
tamatergic nerve terminals, leading to a facilitation of the activity of
nigral GABAergic efferences and to the concomitant impairment of
motor activity usually associated with such increase (see Hauber,
1998), rather than by acting directly on oxytocin receptors localized in
nigrostriatal dopaminergic neurons. In fact, in intact rats the net effect
of an increase in nigral oxytocinergic tone (as that induced by exoge-
nous oxytocin given into the substantia nigra) results in a decreased lo-
comotor activity, while the net effect of the elimination of the
endogenous oxytocinergic tone (as it occurswhen the oxytocin receptor
antagonist d(CH2)5Tyr(Me)2-Orn8-vasotocin is injected bilaterally into
the subtantia nigra, and evenmoremarkedlywhen nigral neurons bear-
ing oxytocinergic receptors, e.g., dopaminergic and glutamatergic, aredestroyed by OXY-SAP) is an increased basal level of locomotor activity
(Fig. 12).
The interpretation given above of the ability of oxytocin to inﬂuence
locomotor activity is in line with the canonical view that the main out-
put from the substantia nigra to the thalamic nucleus is represented by
GABAergic neurons, which control thalamo-cortical neurons andwhose
activity is controlled among others by glutamatergic neurons originat-
ing in the subthalamic nucleus (Fig. 12). However, the possibility that
oxytocin may act on, or that OXY-SAP may also destroy other neuro-
transmitter/neuropeptide containing neurons bearing oxytocin recep-
tors that have not been investigated in this study or considered in the
interpretation given above, which can inﬂuence locomotor activity at
the level of the substantia nigra, cannot be completely ruled out.
Among these are dopaminergic and glutamatergic neurons that project
to the thalamus and its nuclei, both of which can modulate the activity
of thalamocortical neurons and inﬂuence motor activity and other tha-
lamic functions (see Yagüe et al., 2013; Yamaguchi et al., 2013, Morales
and Root, 2014 and references therein). If oxytocinergic receptors are
also present in the cell bodies of these nigrothalamic neurons, their
stimulation by oxytocin or their blockade by d(CH2)5Tyr(Me)2-Orn8-
vasotocin or their destruction by OXY-SAP may contribute to modulate
in opposite manner the activity of the thalamic efferences to the
substantia nigra, hence contributing to the ﬁnal level of motor activity
together with the mechanisms considered above. Interestingly, in
adult rats a few of these nigrothalamic neurons have been found to con-
tain both TH and VGLU T2, as if they were also able to release both do-
pamine and glutamic acid (Yamaguchi et al., 2013). Similar neurons
(e.g., positive for TH and VGluT2) have been found in the ventral teg-
mental area with higher frequency than in the substantia nigra pars
compacta (see Morales and Root, 2014, Antal et al., 2014). Unfortu-
nately, whether oxytocin inﬂuences locomotor activity by acting on
oxytocinergic receptors localized in the surface of nigrothalamic neu-
rons positive for TH, VGlutT2 or both, cannot be determined from our
immunohistochemical results, since in our experimental conditions
VGluTs immunolabeling is usually observed in synapses only and not
in cell perykaria. Another point that needs further investigation is the
quantiﬁcation of the real effect of OXY-SAP on the number of oxytocin
receptors in the substantia nigra in our experimental conditions. This
may be accomplished by using receptor autoradiography and analyzing
oxytocin receptor binding density in the substantia nigra or bymeasur-
ing the expression of the oxytocin receptor protein in OXY-SAP-,
BLANK-SAP- and PBS-treated rats with classic Western Blot analytical
techniques.
Despite the uncertainties discussed above, the ability of oxytocin to
inﬂuence locomotor activity by acting on different neural systems at
the level of the substantia nigra, suggests that the neuropeptide may
play a modulatory role in the control of locomotion. In this regard, it is
noteworthy that the degeneration of dopaminergic nigrostriatal neu-
rons plays a major role in the motor disabilities of Parkinson's disease,
such as bradykinesia, rigidity, resting tremor and postural instability
(see Lees et al., 2009), and that a signiﬁcant decrease in the number of
oxytocin-immunoreactive neurons was also reported in the hypothala-
mus of patients affected by Parkinson's disease (Purba et al., 1994). Such
a decrease was tentatively related to the increased appetite or to the
sexual impotence usually observed in these patients (Purba et al.,
1994), in linewith thewell known inhibitory role of oxytocin in feeding
(Maguire et al., 2013) and the facilitatory one on penile erection and
sexual behavior (see Argiolas and Melis, 2004, 2013; Melis and
Argiolas, 2011, Gil et al., 2013). Oxytocinwas also found able to produce
an amelioration of the rotenone-induced dopaminergic cell death in the
striatum and a suppression of exaggerated striatal neuronal oscillations
in a rat model of Parkinson's disease (Erbaş et al., 2012; Erbas et al.,
2013). As the majority of oxytocinergic neurons present in the brain
originate from the paraventricular nucleus of the hypothalamus and
surrounding periventricular regions, it is likely that the decrease in the
number of oxytocinergic neurons found in patients with Parkinson's
37L. Angioni et al. / Hormones and Behavior 83 (2016) 23–38disease also reﬂects a decrease of oxytocin levels in the substantia nigra
and other brain areas receiving oxytocinergic projections. Togetherwith
the ability of oxytocin to inﬂuence locomotor activity, this raises the
possibility that such a decrease may play a role in the motor disabilities
found in these patients.Whether oxytocinmay be considered as a target
for controlling motor disturbances, as those occurring in Parkinson's
disease and/or in other motor disturbances related to basal ganglia dys-
functions, remain to be evaluated.
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